Antonia S New, MD Email Antonia New
- PROFESSOR | Psychiatry
- Hospital Affiliation
- The Mount Sinai Hospital
Dr. New is Professor, Residency Training Director and Vice Chair for Education in the Department of Psychiatry at Mount Sinai. Dr. New has a longstanding career as a funded principal investigator studying the neurobiology of borderline personality disorder. Her research focus is on emotion dysregulation and emotional interoception abnormalities in borderline personality disorder, symptom domains which underlie some of the interpersonal difficulties encountered in this disorder. In addition, Dr. New explores individual differences in response to stress and trauma, focusing on how this relates to emotion regulation. She uses brain imaging techniques, genetic studies, and laboratory assessment of behavior to explore neural circuitry and mechanisms of treatment response in BPD. In addition, Dr. New has been a teacher and mentor to medical students, residents and post-doctoral fellows throughout her career. She was Director of Medical Student Education in the Department of Psychiatry at The Icahn School of Medicine at Mount Sinai prior to rising to the position of Residency Training Director and Vice Chair for Education. Dr. New has won several awards for teaching and scholarship. She completed her residency in psychiatry at New York Hospital/ Payne Whitney Clinic and a postdoctoral research fellowship at Mount Sinai. She received her medical degree from Cornell University School of Medicine.
Financial & Billing Information
Please direct any detailed billing or financial inquires to the Mount Sinai Psychiatry billing customer service number at 212-659-8752.
MD, Cornell University Medical College
Residency, Internal Medicine
New York Hospital - Cornell Medical Center
Payne Whitney Clinic
Mount Sinai Hospital
Dr. New's research focuses on the neurobiology of borderline personality disorder. Her work explores the regulation of emotion in this disorder using techniques such as functional and structural brain imaging, psychophysiology, neurocognitive tasks and techniques in social neuroscience. Her work has examine the neural circuitry underlying the control of aggression, but more recently has employed a theoretical framework from the philosophy of mind to understand the experience of emotion in this complex disorder.
In addition to borderline personality disorder, Dr. New explores the effect of trauma in women with particular focus on factors that create vulnerability and resilience to adverse consequences of traumatic experiences, also employing functional brain imaging and neurocognitive tasks.
Key words: Social neuroscience, borderline personality disorder, mentalization, resilience, functional MRI, positron emission tomography
To find out more, please see Mood and Personality Disorders Research Program
An Exploratory Phase II Study to Determine the Safety and Tolerability and activity of a Novel Vasopressin 1a Receptor Antagonist in Adults with DSM-5 Intermittent Explosive Disorder (IED)
This exploratory Phase II study has been designed to examine the safety and tolerability profile, and to compare the activity of the novel V1a vasopressin antagonist (sponsored by Azevan Pharmaceuticals) against placebo, in adults with DSM-5 Intermittent Explosive Disorder (IED)....
A D1 Agonist for Working Memory Enhancement in the Schizophrenia
Cognitive deficits, particularly impairments in working memory and executive function, are a core problem of schizophrenia-spectrum conditions. Moreover, working memory and executive function impairments predict functional outcomes, particularly in the schizophrenia-spectrum; how...
New as, Triebwasser j, Charney ds. The Case for Shifting Borderline Personality Disorder to Axis I. Biol Psychiatry 2008 Jun 10; [Epub ahead of print].
New as, Goodman m, Triebwasser j, Siever lj. Recent advances in the biological study of personality disorders. Psychiatr Clin North Am 2008 Sept; 31(3).
Minzenberg mj, Fan j, New as, Tang cy, Siever lj. Frontolimbic structural changes in borderline personality disorder. J Psychiatr Res 2008; 42(9).
Minzenberg mj, Fan j, New as, Tang cy, Siever lj. Frontolimbic dysfunction in response to facial emotion in borderline personality disorder: an event-related fMRI study. Psychiatry Res 2007 Aug 15; 155(3).
Hazlett ea, Speiser lj, Goodman m, Roy m, Carrizal m, Wynn jk, Williams wc, Romero m, Minzenberg mj, Siever lj, New as. Exaggerated Affect-Modulated Startle During Unpleasant Stimuli in Borderline Personality Disorder. Biological Psychiatry 2007; 62(3).
New as, Hazlett ea, Buchsbaum ms, Goodman m, Mitelman sa, Newmark r, Trisdorfer r, Haznedar mm, Koenigsberg hw, Flory j, Siever lj. Amygdala-Prefrontal Disconnection in Borderline Personality Disorder. Neuropsychopharmacology 2007; 32(7).
Hazlett ea, New as, Newmark r, Haznedar mm, Lo jn, Speiser lj, Chen ad, Mitropoulou v, Minzenberg m, Siever lj, Buchsbaum ms. Reduced Anterior and Posterior Cingulate Gray Matter in Borderline Personality Disorder. Biol Psychiatry 2005 Oct 15; 58(8).
New as, Buchsbaum ms, Hazlett ea, Goodman m, Koenigsberg hw, Lo j, Iskander l, Newmark r, Brand j, O'Flynn k, Siever lj. Fluoxetine increases relative metabolic rate in prefrontal cortex in impulsive aggression. Psychopharmacology (Berl) 2004 Nov; 176(3-4).
New as, Hazlett ea, Buchsbaum ms, Goodman m, Reynolds d, Mitropoulou v, Sprung l, Shaw rb, Koenigsberg h, Platholi j, Silverman j, Siever lj. Blunted prefrontal cortical FDG-PET response to meta-chlorophenylpiperazine in impulsive aggression. Arch Gen Psychiatry 2002; 59(7).
New as, Gelernter j, Goodman m, Mitropoulou v, Koenigsberg hw, Silverman jm, Siever lj. Suicide, impulsive aggression and HTR1B genotype. Biol Psychiatry 2001; 50(1).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. New during 2017 and/or 2018. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
- AVANIR Pharmaceuticals
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.